【摘要】 目的：探讨尼可地尔联合曲美他嗪治疗冠心病心绞痛的临床效果。方法：选取2020年3月—2022年3月湖南省人民医院收治的76例冠心病心绞痛患者为研究对象。采用完全双盲法分为对照组和试验组，各38例。对照组予以尼可地尔片治疗，试验组予以尼可地尔片联合曲美他嗪治疗。观察两组氧化应激指标及血液流变学指标，并评估两组疗效及不良反应。结果：治疗前，两组氧化应激指标比较，差异无统计学意义（P>0.05）；治疗后，两组氧化型低密度脂蛋白（ox-LDL）、脂质过氧化物（LPO）、丙二醛（MDA）水平均低于治疗前，超氧化物歧化酶（SOD）水平高于治疗前，且试验组ox-LDL、LPO、MDA水平均低于对照组，SOD水平高于对照组，差异有统计学意义（P<0.05）。治疗前，两组血液流变学指标比较，差异无统计学意义（P>0.05）；治疗后，两组全血高切黏度（HS）、全血低切黏度（LS）、血浆黏度（PV）、纤维蛋白原（FIB）、红细胞比容（HCT）、红细胞沉降率（ESR）水平均低于治疗前，且试验组均低于对照组，差异有统计学意义（P<0.05）。试验组治疗总有效率为89.47%，高于对照组的71.05%，差异有统计学意义（P<0.05）。试验组不良反应总发生率为21.05%，高于对照组的18.42%，但两组间比较，差异无统计学意义（P>0.05）。结论：尼可地尔片联合曲美他嗪治疗冠心病心绞痛患者，可改善机体氧化应激反应，纠正血液流变学异常，缓解心绞痛症状，且联合用药不会增加不良反应。更多还原

【Abstract】 Objective: To investigate the clinical effect of Nicordil combined with Trimetazidine in the treatment of angina pectoris of coronary heart disease. Method: A total of 76 patients with angina pectoris of coronary heart disease treated in Hunan Provincial People’s Hospital from March 2020 to March 2022 were selected as the study objects. The patients were divided into control group and experimental group by completely double-blind method, with 38 cases in each group. The control group was treated with Nicordil Tablets, and the experimental group was treated with Nicordil Tablets combined with Trimetazidine. The indexes of oxidative stress and hemorheology of the two groups were observed, and the efficacy and adverse reactions of the two groups were evaluated. Result: Before treatment, there were no significant differences in the level of oxidative stress between the two groups(P>0.05). After treatment, the levels of oxidized low-density lipoprotein(ox-LDL), lipid peroxides(LPO) and malondialdehyde(MDA) in both groups were lower than those before treatment, and the level of superoxide dismutase(SOD) were higher than those before treatment, and the levels of ox-LDL,LPO and MDA in experimental group were lower than those in control group, and the level of SOD in experimental group was higher than that in control group, the differences were statistically significant(P<0.05). Before treatment, there were no significant differences in hemorheology indexes between the two groups(P>0.05). After treatment, the levels of whole blood high shear viscosity(HS), whole blood low shear viscosity(LS), plasma viscosity(PV), fibrinogen(FIB), hematocrit(HCT) and erythrocyte sedimentation rate(ESR) in two groups were lower than those before treatment, and the experimental group were lower than those in the control group, the differences were statistically significant(P<0.05). The total effective rate of the experimental group was 89.47%, which was higher than 71.05% of the control group, and the difference was statistically significant(P<0.05). The total incidence of adverse reactions in the experimental group was 21.05%, which was higher than 18.42% in the control group, but there was no statistical significance between the two groups(P>0.05). Conclusion: In the treatment of patients with angina pectoris of coronary heart disease, the combination of Nicordil Tablets and Trimetazidine can improve the oxidative stress response, correct the abnormality of hemorheology, relieve the symptoms of angina pectoris,and the combination will not increase the adverse reactions.更多还原